Alnylam Pharmaceuticals (ALNY) stock price, revenue, and financials

Alnylam Pharmaceuticals market cap is $20.5 b, and annual revenue was $492.85 m in FY 2020

$20.5 B

ALNY Mkt cap, 31-Dec-2021

$492.9 M

Alnylam Pharmaceuticals Revenue FY, 2020
Alnylam Pharmaceuticals Gross profit (FY, 2020)414.8 M
Alnylam Pharmaceuticals Gross profit margin (FY, 2020), %84.2%
Alnylam Pharmaceuticals Net income (FY, 2020)-858.3 M
Alnylam Pharmaceuticals EBIT (FY, 2020)-828.4 M
Alnylam Pharmaceuticals Cash, 31-Dec-2020496.6 M
Alnylam Pharmaceuticals EV20.3 B
Get notified regarding key financial metrics and revenue changes at Alnylam PharmaceuticalsLearn more
Banner background

Alnylam Pharmaceuticals Income Statement

Quarterly

USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

26.6m27.7m20.9m29.9m2.1m33.3m44.7m46.1m99.5m77.5m99.2m

Cost of goods sold

137.0k3.3m4.3m13.3m

Gross profit

1.9m29.9m40.4m86.2m

Gross profit Margin, %

93%90%90%87%

R&D expense

28.1m27.5m26.3m25.3m24.3m21.1m21.7m22.1m22.2m24.2m34.5m43.8m44.7m46.3m58.0m67.0m68.6m96.3m83.2m97.9m87.0m90.6m95.3m96.9m137.6m139.9m129.1m163.9m169.6m

General and administrative expense

10.1m8.9m10.2m8.4m9.0m10.4m11.2m12.8m6.3m5.8m6.8m8.9m11.5m9.9m12.7m14.6m16.0m21.1m18.0m22.4m38.5m45.8m47.6m72.4m84.7m116.5m89.6m112.8m126.8m

Operating expense total

38.2m36.4m36.6m33.7m33.2m31.5m33.0m34.9m28.4m30.0m41.2m52.7m56.2m56.2m70.8m81.6m84.7m117.4m101.2m120.3m125.5m136.4m142.9m169.3m222.3m256.5m218.7m276.7m296.3m

EBIT

(11.6m)(8.7m)(15.7m)(13.1m)(12.4m)(10.9m)(12.1m)(18.1m)(9.8m)(21.3m)(32.2m)(269.1m)(45.0m)(45.2m)(52.2m)(72.9m)(78.3m)(110.0m)(92.4m)(106.7m)(106.5m)(120.5m)(125.8m)(147.4m)(192.4m)(254.6m)(188.8m)(236.3m)(210.2m)

EBIT margin, %

(44%)(32%)(75%)(643%)(12303%)(567%)(528%)(211%)

Interest expense

3.2m604.0k609.0k706.0k799.0k475.0k889.0k1.4m229.0k259.0k278.0k251.0k616.0k1.3m1.0m1.6m1.5m7.1m2.3m2.6m779.0k2.1m2.9m6.1m28.9m9.7m7.6m17.8m

Interest income

641.0k602.0k382.0k322.0k265.0k223.0k271.0k261.0k224.0k

Investment income

(3.9m)(1.2m)(1.1m)(1.0m)(467.0k)(889.0k)(1.1m)(1.6m)270.0k290.0k333.0k693.0k753.0k1.0m1.6m1.6m1.8m2.1m2.2m2.1m2.6m3.3m5.8m6.1m6.8m7.5m8.8m5.5m

Pre tax profit

(14.9m)(9.3m)(16.3m)(13.8m)(13.2m)(9.6m)(21.1m)(32.0m)(268.8m)(44.4m)(43.9m)(51.2m)(71.4m)(76.8m)(103.0m)(90.1m)(141.3m)(163.5m)(244.8m)(181.2m)(218.5m)(181.6m)

Income tax expense

(229.0k)298.0k(562.0k)(2.9m)(2.3m)(62.0k)79.0k445.0k695.0k960.0k575.0k

Net Income

(14.6m)(9.6m)(16.3m)(13.8m)(13.2m)(11.4m)(13.0m)(19.5m)(9.0m)(18.2m)(29.7m)(250.9m)(44.1m)(44.0m)(50.8m)(71.8m)(76.8m)(103.0m)(90.1m)(104.1m)(107.3m)(118.4m)(122.9m)(141.2m)(163.6m)(245.3m)(181.9m)(219.5m)(182.2m)

Alnylam Pharmaceuticals Balance Sheet

Quarterly

USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

66.2m46.9m90.6m67.1m74.3m61.7m48.3m75.8m97.8m25.0m11.8m350.6m80.7m82.7m306.6m151.3m149.2m231.3m271.1m168.5m171.1m408.7m202.0m396.1m361.5m316.6m725.0m1.1b923.3m467.8m580.8m496.7m

Accounts Receivable

6.4m4.9m1.2m1.3m2.0m2.2m4.4m1.9m558.0k460.0k609.0k164.0k89.0k384.0k10.1m9.4m8.1m8.8m9.5m15.1m19.5m15.4m14.6m50.8m3.0m3.4m33.8m30.7m48.1m75.6m69.1m79.1m

Prepaid Expenses

5.1m4.9m7.3m6.9m5.7m3.5m4.2m4.8m8.4m10.3m10.7m13.2m15.1m17.5m27.6m22.2m19.3m18.1m22.0m30.4m66.7m51.9m90.8m81.7m65.6m73.5m98.7m88.3m74.8m

Inventories

11.1m32.0m40.6m54.6m68.3m77.4m66.9m

Current Assets

273.5m244.6m250.7m224.3m180.0m208.5m240.3m235.9m240.1m214.4m199.2m674.1m665.1m643.0m1.1b1.0b1.0b1.1b888.1m747.6m597.2m960.7m993.4m1.7b1.5b1.3b1.4b2.1b1.9b1.6b2.2b2.6b

PP&E

18.6m18.4m17.0m16.3m15.3m13.7m14.2m18.8m19.0m18.0m17.0m15.7m17.0m18.8m21.2m25.2m26.3m36.8m55.4m74.2m130.0m147.5m161.9m202.0m227.8m272.7m341.7m371.8m396.5m429.8m439.1m444.7m

Total Assets

440.2m412.6m369.1m340.8m310.2m340.3m318.5m322.4m471.6m462.6m447.5m1.1b1.0b986.4m1.6b1.5b1.4b1.3b1.4b1.3b1.1b1.4b1.4b1.9b1.8b1.7b2.0b2.7b2.5b2.3b3.4b3.3b

Accounts Payable

10.4m6.6m5.8m7.9m5.5m4.3m5.5m5.1m3.1m4.5m2.7m5.0m6.2m5.2m15.5m15.7m14.3m17.4m12.8m23.1m25.4m23.2m9.2m13.2m12.0m21.8m22.7m71.2m39.4m40.5m26.1m27.9m

Short-term debt

29.0m33.4m32.2m

Current Liabilities

102.0m99.4m99.3m100.5m93.9m66.6m57.1m54.8m49.8m53.1m54.9m83.8m53.7m56.8m80.7m66.6m57.1m66.4m70.6m81.8m95.8m108.7m101.0m115.4m113.7m121.5m149.2m328.6m352.9m338.8m384.3m480.2m

Long-term debt

282.3m277.2m276.5m275.8m281.6m297.3m

Total Debt

150.0m150.0m150.0m150.0m150.0m30.0m30.0m30.0m30.0m30.0m276.5m304.8m315.1m329.5m

Total Liabilities

274.7m252.0m223.5m204.3m182.4m142.9m130.2m145.2m160.0m154.4m149.9m125.3m90.4m81.9m132.3m122.2m114.5m127.9m283.7m297.9m303.0m311.3m299.4m168.3m168.6m197.5m467.0m959.2m934.5m929.9m2.0b2.1b

Common Stock

421.0k422.0k424.0k427.0k427.0k519.0k520.0k524.0k621.0k624.0k632.0k755.0k763.0k767.0k842.0k845.0k847.0k855.0k856.0k858.0k861.0k917.0k924.0k1.0m1.0m1.0m1.1m1.1m1.1m1.1m1.2m1.2m

Preferred Stock

Additional Paid-in Capital

490.6m495.4m504.8m509.8m514.3m609.3m613.1m621.4m806.1m813.6m833.7m1.8b1.8b1.8b2.5b2.5b2.5b2.5b2.6b2.6b2.6b3.0b3.1b4.0b4.0b4.1b4.6b5.0b5.1b5.3b5.5b5.6b

Retained Earnings

(326.8m)(336.4m)(359.6m)(373.5m)(386.7m)(412.4m)(425.3m)(444.8m)(516.0m)(534.2m)(563.9m)(847.2m)(891.3m)(935.2m)(1.0b)(1.1b)(1.2b)(1.3b)(1.4b)(1.5b)(1.8b)(1.9b)(2.0b)(2.2b)(2.4b)(2.6b)(3.0b)(3.2b)(3.5b)(3.9b)(4.1b)(4.3b)

Total Equity

165.5m160.6m145.6m136.6m127.9m197.4m188.3m177.2m311.6m308.2m297.6m955.0m942.3m904.5m1.5b1.4b1.3b1.2b1.1b1.0b830.9m1.1b1.1b1.8b1.6b1.5b1.5b1.8b1.6b1.3b1.4b1.2b

Debt to Equity Ratio

0.1 x0.1 x0.2 x0.1 x0.1 x0 x0 x0 x0 x0 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.1 x0.1 x0 x0 x0 x0 x0 x

Financial Leverage

2.7 x2.6 x2.5 x2.5 x2.4 x1.7 x1.7 x1.8 x1.5 x1.5 x1.5 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.3 x1.3 x1.4 x1.3 x1.3 x1.1 x1.1 x1.1 x1.3 x1.5 x1.6 x1.7 x2.4 x2.7 x

Alnylam Pharmaceuticals Cash Flow

Quarterly

USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(27.0m)(36.6m)(16.3m)(30.1m)(43.3m)(11.4m)(24.3m)(43.8m)(9.0m)(27.2m)(56.9m)(250.9m)(295.0m)(339.0m)(50.8m)(122.6m)(199.4m)(103.0m)(193.1m)(297.2m)(107.3m)(225.7m)(348.6m)(141.2m)(304.8m)(550.1m)(181.9m)(401.4m)(609.9m)(182.2m)(361.4m)(614.7m)

Depreciation and Amortization

2.4m3.7m1.3m2.6m3.9m2.1m4.7m7.0m2.1m4.8m7.6m2.6m5.5m8.6m3.7m8.7m14.0m4.6m8.6m12.1m3.0m6.1m9.7m3.2m5.4m8.7m12.2m22.0m11.7m7.6m15.8m24.4m

Accounts Receivable

(314.0k)1.2m2.3m2.1m1.4m(724.0k)(2.9m)(450.0k)(454.0k)(356.0k)(505.0k)4.1m4.2m3.9m29.8m30.5m31.8m(516.0k)(1.2m)(6.8m)3.9m7.9m8.7m(16.8m)31.0m30.6m(15.0m)(11.9m)(29.7m)(32.9m)(26.1m)(35.1m)

Inventories

(10.4m)(7.1m)(15.0m)(28.1m)(12.0m)(24.2m)(27.0m)

Accounts Payable

(2.1m)(5.9m)(3.5m)(1.4m)(3.8m)(1.5m)(281.0k)(707.0k)(959.0k)470.0k(1.3m)(1.4m)121.0k(826.0k)750.0k(1.2m)(885.0k)347.0k(3.6m)(1.5m)(11.1m)(8.3m)(17.3m)(9.0m)(9.7m)(650.0k)(17.1m)26.4m(3.7m)(14.2m)2.0m75.6m

Cash From Operating Activities

(39.9m)(64.0m)(6.3m)(32.9m)(61.9m)(30.2m)(51.9m)(46.7m)(971.0k)(24.6m)(46.3m)(41.7m)(88.3m)(129.0m)(26.3m)(81.7m)(136.1m)(83.6m)(153.8m)(229.4m)(100.3m)(181.4m)(279.7m)(155.7m)(258.4m)(412.2m)(188.5m)100.2m(82.4m)(246.2m)(381.5m)(491.8m)

Purchases of PP&E

(2.5m)(3.6m)(28.0k)(502.0k)(767.0k)(263.0k)(1.9m)(7.7m)(1.8m)(2.2m)(3.1m)(388.0k)(2.2m)(5.4m)(2.1m)(3.4m)(9.9m)(2.8m)(24.4m)(44.7m)(36.2m)(57.8m)(83.5m)(21.3m)(44.0m)(89.4m)(44.0m)(65.3m)(101.4m)(19.6m)(36.3m)(48.7m)

Capital Expenditures

(9.1m)

Cash From Investing Activities

(34.4m)(29.7m)22.3m24.9m61.2m(65.6m)(58.0m)(40.1m)(130.8m)(184.0m)(186.6m)(379.8m)(608.2m)(570.2m)(341.3m)(448.3m)(399.6m)117.9m73.6m42.2m75.1m7.4m(129.8m)(134.8m)(72.2m)24.0m102.7m(186.7m)(196.8m)113.7m(327.5m)(337.6m)

Long-term Borrowings

(30.0m)

Cash From Financing Activities

3.1m3.1m9.0k471.0k471.0k87.3m87.9m92.4m178.2m182.2m193.3m718.9m724.0m728.8m599.0m606.1m609.7m16.1m170.4m174.8m2.7m389.0m417.9m41.5m47.1m60.1m390.9m803.5m782.8m53.9m742.9m777.0m

Net Change in Cash

(71.3m)(90.6m)16.0m(7.5m)(263.0k)(8.5m)(22.0m)5.6m46.4m(26.4m)(39.6m)297.4m27.6m29.6m231.4m76.1m74.0m50.4m90.2m(12.4m)(22.5m)215.1m8.4m(249.0m)(283.4m)(328.1m)305.1m717.0m503.1m(79.2m)33.7m(50.5m)

Free Cash Flow

(92.7m)

Alnylam Pharmaceuticals Ratios

USDQ2, 2010

Financial Leverage

2.7 x

Alnylam Pharmaceuticals Employee Rating

4.3173 votes
Culture & Values
4.1
Work/Life Balance
3.5
Senior Management
3.9
Salary & Benefits
4.1
Career Opportunities
3.8
Source